România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

incyte biosciences distribution b.v. - olanda - ponatinibum - compr. film. - 15mg - inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

incyte biosciences distribution b.v. - olanda - ponatinibum - compr. film. - 30mg - inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

incyte biosciences distribution b.v. - olanda - ponatinibum - compr. film. - 45mg - inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

incyte biosciences distribution b.v. - tarile de jos - tafasitamabum - pulb. pt. conc. pt. sol. perf. - 200mg - anticorpi monoclonali

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 13,5mg - inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 4,5mg - inhibitori de protein-kinaza

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

incyte biosciences distribution b.v. - tarile de jos - pemigatinibum - compr. - 9mg - inhibitori de protein-kinaza

Uniunea Europeană - română - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. vezi secțiunile 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Uniunea Europeană - română - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - agenți antineoplazici - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agenți antineoplazici - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).